BCG029
/ Biocytogen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
BCG029: An ADAM9-targeting ADC featuring a novel topoisomerase I inhibitor payload demonstrated potent efficacy in PDX models
(AACR 2026)
- "Abstract is embargoed at this time."
ADC • Clinical • Late-breaking abstract • Oncology • ADAM9
1 to 1
Of
1
Go to page
1